Original language | English |
---|---|
Pages (from-to) | e251-e258 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 19 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 19, No. 6, 06.2019, p. e251-e258.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - When Monoclonal Gammopathy is of Renal Significance
T2 - A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds
AU - Gilmore, Brendan A.
AU - Rodby, Roger A.
AU - Cimbaluk, David
AU - Venugopal, Parameswaran
AU - Patel, Pritesh
AU - Barton, Kevin
AU - Hagen, Patrick
AU - Rodriguez, Tulio
AU - Sumoza, Luis
AU - Bishop, Michael R.
AU - Dhakal, Binod
AU - Hari, Parameswaran
AU - Paner, Agne
N1 - Funding Information: P. Patel reports speakers bureau for Celgene, Janssen, and Amgen; consulting for Celgene and Amgen. P. Hari reports receiving honoraria for consulting from Celgene , Takeda , BMS, and Janssen; and research grants from Celgene and Takeda. P. Venugopal reports consulting for AbbVie and Bayer. M. Bishop reports speakers bureau for Celgene. T. Rodriguez reports speakers bureau and advisor for BMS and Takeda; research support from Celgene, Amgen. B. Gilmore has stated that he has no conflicts of interest. Agne Paner: Consulting and honoraria: Takeda, Abbvie, Celgene, Amgen, Janssen. Funding Information: P. Patel reports speakers bureau for Celgene, Janssen, and Amgen; consulting for Celgene and Amgen. P. Hari reports receiving honoraria for consulting from Celgene, Takeda, BMS, and Janssen; and research grants from Celgene and Takeda. P. Venugopal reports consulting for AbbVie and Bayer. M. Bishop reports speakers bureau for Celgene. T. Rodriguez reports speakers bureau and advisor for BMS and Takeda; research support from Celgene, Amgen. B. Gilmore has stated that he has no conflicts of interest. Agne Paner: Consulting and honoraria: Takeda, Abbvie, Celgene, Amgen, Janssen.
PY - 2019/6
Y1 - 2019/6
UR - http://www.scopus.com/inward/record.url?scp=85064179757&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.02.008
DO - 10.1016/j.clml.2019.02.008
M3 - Article
C2 - 30987953
AN - SCOPUS:85064179757
SN - 2152-2650
VL - 19
SP - e251-e258
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -